Ottimo Pharma Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$143M
- Investors
-
11
Ottimo Pharma General Information
Description
Developer of cancer therapeutics designed to treat solid tumors. The company offers a bi-functional antibody that targets both immune checkpoint inhibition and angiogenesis which are pathways involved in cancer growth, enabling healthcare professionals with a dual-pathway approach that has the potential to provide effective treatment for cancer patients by attacking the disease from multiple angles.
Contact Information
Website
www.ottimopharma.comCorporate Office
- C/O Kreston Reeves Llp Innovation House
- Ramsgate Road, Kent
- Sandwich CT13 9FF
- England, United Kingdom
Corporate Office
- C/O Kreston Reeves Llp Innovation House
- Ramsgate Road, Kent
- Sandwich CT13 9FF
- England, United Kingdom
Ottimo Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A) | 19-Dec-2024 | $143M | Completed | Generating Revenue | ||
| 2. Early Stage VC | 06-Oct-2020 | Completed | Startup | |||
| 1. Seed Round | 06-Apr-2017 | $856K | $856K | Completed | Startup |
Ottimo Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| B Ordinary | ||||||||
| Series B | 4,497,069 | $0.000013 | $1.28 | $1.28 | 1x | $1.28 | 26.54% | |
| Series A | 800,000 | $0.000013 | $1.09 | $1.09 | 1x | $1.09 | 4.72% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Ottimo Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ottimo Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ottimo Pharma Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avoro Capital | Venture Capital | Minority | ||
| Decheng Capital | Venture Capital | Minority | ||
| Invus (Private Equity) | PE/Buyout | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| JPMorgan Life Sciences Private Capital | Venture Capital | Minority |
Ottimo Pharma FAQs
-
When was Ottimo Pharma founded?
Ottimo Pharma was founded in 2017.
-
Where is Ottimo Pharma headquartered?
Ottimo Pharma is headquartered in Sandwich, United Kingdom.
-
What is the size of Ottimo Pharma?
Ottimo Pharma has 20 total employees.
-
What industry is Ottimo Pharma in?
Ottimo Pharma’s primary industry is Drug Discovery.
-
Is Ottimo Pharma a private or public company?
Ottimo Pharma is a Private company.
-
What is the current valuation of Ottimo Pharma?
The current valuation of Ottimo Pharma is .
-
What is Ottimo Pharma’s current revenue?
The current revenue for Ottimo Pharma is .
-
How much funding has Ottimo Pharma raised over time?
Ottimo Pharma has raised $150M.
-
Who are Ottimo Pharma’s investors?
Avoro Capital, Decheng Capital, Invus (Private Equity), Janus Henderson Investors, and JPMorgan Life Sciences Private Capital are 5 of 11 investors who have invested in Ottimo Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
